Location of Repository

Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis

By Pamela Zengel, Diana Ramp, Brigitte Mack, Stefan Zahler, Alexander Berghaus, Bernd Muehlenweg, Olivier Gires and Suna Schmitz

Abstract

Background: Squamous cell carcinoma of the head and neck (SCCHN) are highly invasive tumours with frequent local and distant recurrence. Metastasis formation requires degradation of the extracellular matrix, which is fulfilled by membrane-associated proteases such as the urokinase plasminogen activator (uPA). WX-UK1 is a competitive active site inhibitor of the protease function of uPA that impairs on the capacity of tumour cells to invade in vitro. Methods: In the present study, effects of combinations of WX-UK1 with matrix metalloprotease inhibitors (MMP, galardin®) and cyclooxygenase-2 (COX-2, celecoxib®) inhibitors on tumour cell proliferation, invasion, and angiogenesis induction were evaluated. Matrigel invasion chambers and a spheroid co-cultivation model with human fibroblast served to determine the invasive potential of both FaDu (SCCHN) and HeLa (cervical carcinoma) cells, each treated with combinations of Celecoxib®, Galardin®, and WX-UK1. Results: Blocking of single protease systems resulted in a significant 50% reduction of tumour cell invasion using WX-UK1, while the triple combination was even more effective with 80% reduction of invasion. Additionally, a sprouting assay with HUVEC was used to test the anti-angiogenetic potential of the triple combination, resulting in a 40% decrease in the sprouting rate. Conclusions: A combined approach targeting different families of proteases and cyclooxygenases represents a promising adjuvant therapy.

Topics: Chemie und Pharmazie, ddc:540
Year: 2010
DOI identifier: 10.1186/1471-2407-10-92
OAI identifier: oai:epub.ub.uni-muenchen.de:14385
Provided by: Open Access LMU

Suggested articles

Preview

Citations

  1. (2002). [Clinical and epidemiological data of patients with malignomas of the head and neck]. Laryngorhinootologie doi
  2. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med doi
  3. (1998). Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. doi
  4. (2004). De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett doi
  5. (2007). EJ: The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. doi
  6. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell doi
  7. (2000). et al: A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol
  8. (2009). Friedl P: Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metastasis doi
  9. (2007). Gires O: EpCAM (CD326) finding its role in cancer.
  10. (2004). Gires O: Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. doi
  11. (1999). Hong WK: Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg
  12. (1998). Itohara S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res
  13. (1996). JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med doi
  14. (2002). Knuechel R: Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol
  15. (1992). Kvietys PR: Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. doi
  16. (2008). Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer doi
  17. (1999). Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res
  18. (1997). Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. doi
  19. (2002). Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science doi
  20. (2005). Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res
  21. (2000). Multiagent chemopreventive agent combinations. doi
  22. (1997). O’Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature
  23. (1999). P: 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett doi
  24. (2009). Rao JS: Concepts in in vivo siRNA delivery for cancer therapy. doi
  25. (2009). Rao JS: Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol doi
  26. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. doi
  27. (1994). RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature doi
  28. (1983). Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell doi
  29. (1999). RN: Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia doi
  30. (1999). RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene doi
  31. (1994). SG: Inhibition of collagenolytic activity relates to quantitative reduction of invasion in vitro in a c-Ha-ras transfected glial cell line. doi
  32. (2006). Spizzo G: Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. doi
  33. (1999). Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol doi
  34. (1999). Tarnawski AS: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med
  35. (2009). The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets doi
  36. (1999). Tsukuda M: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. doi
  37. (2008). Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res doi
  38. (2005). Udagawa Y: Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. doi
  39. (1998). Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. doi
  40. (2000). Weinberg RA: The hallmarks of cancer. Cell doi
  41. (1994). Wilmes E: [Micrometastases in bone marrow of patients with cancers in the head and neck area]. Laryngorhinootologie

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.